Skip to main content
Clinical hold issued for Unum's non-Hodgkin lymphoma drug

The FDA issued a clinical hold on an early-stage trial for Unum Therapeutics' ACTR087, in combination with Roche's Rituxan, or rituximab, which are being evaluated as a treatment for patients with relapsed or refractory CD20-positive B cell non-Hodgkin lymphoma after treatment with lymphodepleting chemotherapy. The hold followed a report of major neurotoxicity, cytomegalovirus infection and life-endangering respiratory distress in a patient enrolled in the study.

Full Story: